Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  HIV Infection

  Free Subscription


Articles published in J Virol

Retrieve available abstracts of 202 articles:
HTML format



Single Articles


    September 2024
  1. ZANKHARIA U, Yi Y, Lu F, Vladimirova O, et al
    HIV-induced RSAD2/Viperin supports sustained infection of monocyte-derived macrophages.
    J Virol. 2024 Sep 11:e0086324. doi: 10.1128/jvi.00863.
    PubMed     Abstract available


  2. MARCHITTO L, Richard J, Prevost J, Tauzin A, et al
    The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.
    J Virol. 2024 Sep 9:e0101624. doi: 10.1128/jvi.01016.
    PubMed     Abstract available


  3. ZHANG S, Anang S, Zhang Z, Nguyen HT, et al
    Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs.
    J Virol. 2024 Sep 9:e0063124. doi: 10.1128/jvi.00631.
    PubMed     Abstract available


  4. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
    Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
    J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
    PubMed     Abstract available


  5. TAUZIN A, Marchitto L, Belanger E, Benlarbi M, et al
    Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.
    J Virol. 2024 Sep 4:e0096024. doi: 10.1128/jvi.00960.
    PubMed     Abstract available


  6. ZHANG W, Nilles TL, Bream JH, Li H, et al
    Breadth and polyfunctionality of T cell responses to human cytomegalovirus in men who have sex with men: relationship with HIV infection and frailty.
    J Virol. 2024 Sep 4:e0116724. doi: 10.1128/jvi.01167.
    PubMed     Abstract available


    August 2024
  7. BRACKENRIDGE S, John N, He W, Fruh K, et al
    Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.
    J Virol. 2024 Aug 29:e0120624. doi: 10.1128/jvi.01206.
    PubMed     Abstract available


  8. ZHANG Y, Zhang M, Wu H, Wu X, et al
    Afucosylated anti-EBOV antibody MIL77-3 engages sGP to elicit NK cytotoxicity.
    J Virol. 2024 Aug 20:e0068524. doi: 10.1128/jvi.00685.
    PubMed     Abstract available


  9. BARBOSA BOMFIM CC, Genin H, Cottoignies-Callamarte A, Gallois-Montbrun S, et al
    CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients.
    J Virol. 2024 Aug 20:e0012824. doi: 10.1128/jvi.00128.
    PubMed     Abstract available


  10. MUECKSCH F, Klaus S, Laketa V, Muller B, et al
    Probing Gag-Env dynamics at HIV-1 assembly sites using live-cell microscopy.
    J Virol. 2024 Aug 13:e0064924. doi: 10.1128/jvi.00649.
    PubMed     Abstract available


  11. MU Z, Whitley J, Martik D, Sutherland L, et al
    Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
    J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137.
    PubMed     Abstract available


    July 2024
  12. ZHOU M, Yang T, Yuan M, Li X, et al
    ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latency.
    J Virol. 2024 Jul 31:e0003524. doi: 10.1128/jvi.00035.
    PubMed     Abstract available


  13. NELSON GW, van Duijn J, Yuki Y, Pau MG, et al
    Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
    J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281.
    PubMed     Abstract available


  14. REYES BALLISTA JM, Hoover AJ, Noble JT, Acciani MD, et al
    Chikungunya virus release is reduced by TIM-1 receptors through binding of envelope phosphatidylserine.
    J Virol. 2024 Jul 15:e0077524. doi: 10.1128/jvi.00775.
    PubMed     Abstract available


    June 2024
  15. KUSE N, Noyori O, Takahashi N, Zhang Y, et al
    Recognition of HIV-1-infected fibrocytes lacking Nef-mediated HLA-B downregulation by HIV-1-specific T cells.
    J Virol. 2024 Jun 28:e0079124. doi: 10.1128/jvi.00791.
    PubMed     Abstract available


  16. ROESMANN F, Sertznig H, Klaassen K, Wilhelm A, et al
    The interferon-regulated host factor hnRNPA0 modulates HIV-1 production by interference with LTR activity, mRNA trafficking, and programmed ribosomal frameshifting.
    J Virol. 2024 Jun 20:e0053424. doi: 10.1128/jvi.00534.
    PubMed     Abstract available


  17. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
    Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
    J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
    PubMed     Abstract available


    May 2024
  18. NAZZIWA J, Andrews SM, Hou MM, Bruhn CAW, et al
    Higher HIV-1 evolutionary rate is associated with cytotoxic T lymphocyte escape mutations in infants.
    J Virol. 2024 May 30:e0007224. doi: 10.1128/jvi.00072.
    PubMed     Abstract available


  19. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
    Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.
    J Virol. 2024 May 24:e0033524. doi: 10.1128/jvi.00335.
    PubMed    


  20. RAHMBERG AR, Markowitz TE, Mudd JC, Ortiz AM, et al
    SIV infection and ARV treatment reshape the transcriptional and epigenetic profile of naive and memory T cells in vivo.
    J Virol. 2024 May 23:e0028324. doi: 10.1128/jvi.00283.
    PubMed     Abstract available


  21. WEBB GM, Pessoa CT, McCullen AJ, Hwang JM, et al
    Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.
    J Virol. 2024 May 22:e0027324. doi: 10.1128/jvi.00273.
    PubMed     Abstract available


  22. VERBEEK R, Vandekerckhove L, Van Cleemput J
    Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research.
    J Virol. 2024 May 8:e0043724. doi: 10.1128/jvi.00437.
    PubMed     Abstract available


    April 2024
  23. PERSAUD AT, Khela J, Fernandes C, Chaphekar D, et al
    Virion-incorporated CD14 enables HIV-1 to bind LPS and initiate TLR4 signaling in immune cells.
    J Virol. 2024 Apr 25:e0036324. doi: 10.1128/jvi.00363.
    PubMed     Abstract available


  24. YANG Q, Wang J, Chen Z
    Conditional splicing system for tight control of viral overlapping genes.
    J Virol. 2024;98:e0024224.
    PubMed     Abstract available


    March 2024
  25. VON MALTITZ P, Wettstein L, Weil T, Schommers P, et al
    Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies.
    J Virol. 2024 Mar 19:e0119023. doi: 10.1128/jvi.01190.
    PubMed     Abstract available


  26. TWENTYMAN J, Emerman M, Ohainle M
    Capsid-dependent lentiviral restrictions.
    J Virol. 2024 Mar 18:e0030824. doi: 10.1128/jvi.00308.
    PubMed     Abstract available


    February 2024
  27. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
    A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
    J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
    PubMed     Abstract available


  28. FENTON AD, Archin N, Turner A-M, Joseph S, et al
    A novel high-throughput microwell outgrowth assay for HIV-infected cells.
    J Virol. 2024 Feb 20:e0179823. doi: 10.1128/jvi.01798.
    PubMed     Abstract available


  29. YANG Q, Barbachano-Guerrero A, Fairchild LM, Rowland TJ, et al
    Macrophages derived from human induced pluripotent stem cells (iPSCs) serve as a high-fidelity cellular model for investigating HIV-1, dengue, and influenza viruses.
    J Virol. 2024 Feb 7:e0156323. doi: 10.1128/jvi.01563.
    PubMed     Abstract available


  30. BOSE D, Deb Adhikary N, Xiao P, Rogers KA, et al
    SHIV-C109p5 NHP induces rapid disease progression in elderly macaques with extensive GI viral replication.
    J Virol. 2024 Feb 1:e0165223. doi: 10.1128/jvi.01652.
    PubMed     Abstract available


    January 2024
  31. YOSHIDA T, Kasuya Y, Yamamoto H, Kawai G, et al
    HIV-1 RNAs whose transcription initiates from the third deoxyguanosine of GGG tract in the 5' long terminal repeat serve as a dominant genome for efficient provirus DNA formation.
    J Virol. 2024 Jan 30:e0182523. doi: 10.1128/jvi.01825.
    PubMed     Abstract available


  32. WANG Q, Zhang S, Nguyen HT, Sodroski J, et al
    Inhibition of human immunodeficiency virus (HIV-1) infectivity by expression of poorly or broadly neutralizing antibodies against Env in virus-producing cells.
    J Virol. 2024 Jan 30:e0159423. doi: 10.1128/jvi.01594.
    PubMed     Abstract available


  33. SHAHID A, MacLennan S, Jones BR, Sudderuddin H, et al
    The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time.
    J Virol. 2024 Jan 12:e0165523. doi: 10.1128/jvi.01655.
    PubMed     Abstract available


  34. ALFADHLI A, Romanaggi C, Barklis RL, Barklis E, et al
    Second site reversion of HIV-1 envelope protein baseplate mutations maps to the matrix protein.
    J Virol. 2024 Jan 9:e0174223. doi: 10.1128/jvi.01742.
    PubMed     Abstract available


  35. VERDEJO-TORRES O, Vargas-Pavia T, Fatima S, Clapham PR, et al
    Implications of the 375W mutation for HIV-1 tropism and vaccine development.
    J Virol. 2024 Jan 3:e0152223. doi: 10.1128/jvi.01522.
    PubMed     Abstract available


    December 2023
  36. VUKOVICH MJ, Raju N, Kgagudi P, Manamela NP, et al
    Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.
    J Virol. 2023 Dec 12:e0147823. doi: 10.1128/jvi.01478.
    PubMed     Abstract available


  37. MALLORSON R, Miyagi E, Kao S, Sukegawa S, et al
    Transcriptional regulation of the HIV-1 inhibitory factor human mannose receptor 1 by the myeloid-specific transcription factor PU.1.
    J Virol. 2023 Dec 11:e0170223. doi: 10.1128/jvi.01702.
    PubMed     Abstract available


  38. GOBRAN ST, Pagliuzza A, Khedr O, Fert A, et al
    DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
    J Virol. 2023 Dec 5:e0110523. doi: 10.1128/jvi.01105.
    PubMed     Abstract available


    November 2023
  39. MIN AK, Javidfar B, Missall R, Doanman D, et al
    HIV-1 infection of genetically engineered iPSC-derived central nervous system-engrafted microglia in a humanized mouse model.
    J Virol. 2023 Nov 30:e0159523. doi: 10.1128/jvi.01595.
    PubMed     Abstract available


  40. LEE S-C, Naik NG, Tombacz D, Gulyas G, et al
    Hypoxia and HIF-1alpha promote lytic de novo KSHV infection.
    J Virol. 2023;97:e0097223.
    PubMed     Abstract available


  41. CHANG J, Parent LJ
    HIV-1 Gag co-localizes with euchromatin histone marks at the nuclear periphery.
    J Virol. 2023 Nov 22:e0117923. doi: 10.1128/jvi.01179.
    PubMed     Abstract available


  42. YAPO V, Majumder K, Tedbury PR, Wen X, et al
    HIV-2 inhibits HIV-1 gene expression via two independent mechanisms during cellular co-infection.
    J Virol. 2023 Nov 22:e0187022. doi: 10.1128/jvi.01870.
    PubMed     Abstract available


  43. LIU Y, Binda CS, Berkhout B, Das AT, et al
    CRISPR-Cas attack of HIV-1 proviral DNA can cause unintended deletion of surrounding cellular DNA.
    J Virol. 2023 Nov 20:e0133423. doi: 10.1128/jvi.01334.
    PubMed     Abstract available


    October 2023
  44. YANDRAPALLY S, Sarkar S, Banerjee S
    HIV-1 Tat commandeers nuclear export of Rev-viral RNA complex by controlling hnRNPA2-mediated splicing.
    J Virol. 2023 Oct 31:e0104423. doi: 10.1128/jvi.01044.
    PubMed     Abstract available


  45. ANANG S, Zhang S, Fritschi C, Chiu T-J, et al
    V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins.
    J Virol. 2023 Oct 27:e0117123. doi: 10.1128/jvi.01171.
    PubMed     Abstract available


  46. WANG L, Howell MEA, Hensley CR, Ning K, et al
    The master antioxidant defense is activated during EBV latent infection.
    J Virol. 2023 Oct 25:e0095323. doi: 10.1128/jvi.00953.
    PubMed     Abstract available


  47. KUSE N, Gatanaga H, Zhang Y, Chikata T, et al
    Epitope-dependent effect of long-term cART on maintenance and recovery of HIV-1-specific CD8(+) T cells.
    J Virol. 2023 Oct 25:e0102423. doi: 10.1128/jvi.01024.
    PubMed     Abstract available


  48. EVANGELOUS TD, Berry M, Venkatayogi S, LeMaster C, et al
    Host immunity associated with spontaneous suppression of viremia in therapy-naive young rhesus macaques following neonatal SHIV infection.
    J Virol. 2023 Oct 24:e0109423. doi: 10.1128/jvi.01094.
    PubMed     Abstract available


  49. PADRON A, Prakash P, Pandhare J, Luban J, et al
    Emerging role of cyclophilin A in HIV-1 infection: from producer cell to the target cell nucleus.
    J Virol. 2023 Oct 16:e0073223. doi: 10.1128/jvi.00732.
    PubMed     Abstract available


  50. BARTON K, Ferguson JM, Deveson IW, Falcinelli SD, et al
    HIVepsilon-seq-scalable characterization of intact persistent proviral HIV reservoirs in women.
    J Virol. 2023 Oct 16:e0070523. doi: 10.1128/jvi.00705.
    PubMed     Abstract available


  51. SONG E, Lee SK, Dykxhoorn DM, Novina C, et al
    Correction for Song et al., "Sustained Small Interfering RNA-Mediated Human Immunodeficiency Virus Type 1 Inhibition in Primary Macrophages".
    J Virol. 2023 Oct 13:e0093623. doi: 10.1128/jvi.00936.
    PubMed    


  52. VAN DUIJN J, Stieh D, Fernandez N, King D, et al
    Mosaic HIV-1 vaccination induces anti-viral CD8(+) T cell functionality in the phase 1/2a clinical trial APPROACH.
    J Virol. 2023 Oct 9:e0112623. doi: 10.1128/jvi.01126.
    PubMed     Abstract available


  53. LERNER G, Ding L, Spearman P
    Tryptophan-based motifs in the LLP3 region of the HIV-1 envelope glycoprotein cytoplasmic tail direct trafficking to the endosomal recycling compartment and mediate particle incorporation.
    J Virol. 2023 Oct 5:e0063123. doi: 10.1128/jvi.00631.
    PubMed     Abstract available


    September 2023
  54. PINCUS SH, Stackhouse M, Watt C, Ober K, et al
    Soluble CD4 and low molecular weight CD4-mimetic compounds sensitize cells to be killed by anti-HIV cytotoxic immunoconjugates.
    J Virol. 2023 Sep 29:e0115423. doi: 10.1128/jvi.01154.
    PubMed     Abstract available


  55. NKUWI E, Judicate GP, Tan TS, Barabona G, et al
    Relative resistance of patient-derived envelope sequences to SERINC5-mediated restriction of HIV-1 infectivity.
    J Virol. 2023 Sep 28:e0082323. doi: 10.1128/jvi.00823.
    PubMed     Abstract available


  56. SCHULZ VE, Tuff JF, Tough RH, Lewis L, et al
    Host genetic variation at a locus near CHD1L impacts HIV sequence diversity in a South African population.
    J Virol. 2023 Sep 25:e0095423. doi: 10.1128/jvi.00954.
    PubMed     Abstract available


  57. KRCHLIKOVA V, Lotke R, Haussmann I, Reinisova M, et al
    Independent loss events of a functional tetherin gene in galliform birds.
    J Virol. 2023 Sep 15:e0080323. doi: 10.1128/jvi.00803.
    PubMed     Abstract available


  58. OGUNDIRAN AI, Chang TL, Ivanov A, Kumari N, et al
    Shear-reversible clusters of HIV-1 in solution: stabilized by antibodies, dispersed by mucin.
    J Virol. 2023 Sep 15:e0075223. doi: 10.1128/jvi.00752.
    PubMed     Abstract available


  59. DAHAL S, Clayton K, Cabral T, Cheng R, et al
    On a path toward a broad-spectrum anti-viral: inhibition of HIV-1 and coronavirus replication by SR kinase inhibitor harmine.
    J Virol. 2023 Sep 14:e0039623. doi: 10.1128/jvi.00396.
    PubMed     Abstract available


  60. ZHANG Z, Wang Q, Nguyen HT, Chen HC, et al
    Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation.
    J Virol. 2023 Sep 11:e0059223. doi: 10.1128/jvi.00592.
    PubMed     Abstract available


  61. ZGHEIB S, Taha N, Zeiger M, Glushonkov O, et al
    The human cellular protein NoL12 is a specific partner of the HIV-1 nucleocapsid protein NCp7.
    J Virol. 2023 Sep 11:e0004023. doi: 10.1128/jvi.00040.
    PubMed     Abstract available


  62. RAO PG, Lambert GS, Upadhyay C
    Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    J Virol. 2023 Sep 8:e0071023. doi: 10.1128/jvi.00710.
    PubMed     Abstract available


  63. KHARYTONCHYK S, Burnett C, Gc K, Telesnitsky A, et al
    Transcription start site heterogeneity and its role in RNA fate determination distinguish HIV-1 from other retroviruses and are mediated by core promoter elements.
    J Virol. 2023 Sep 8:e0081823. doi: 10.1128/jvi.00818.
    PubMed     Abstract available


  64. HSIEH SH, Yu FH, Huang KJ, Wang CT, et al
    HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation.
    J Virol. 2023 Sep 6:e0094823. doi: 10.1128/jvi.00948.
    PubMed     Abstract available


  65. HORVATH RM, Brumme ZL, Sadowski I
    CDK8 inhibitors antagonize HIV-1 reactivation and promote provirus latency in T cells.
    J Virol. 2023 Sep 6:e0092323. doi: 10.1128/jvi.00923.
    PubMed     Abstract available


    August 2023
  66. YI Y, Zankharia U, Cassel JA, Lu F, et al
    A high-throughput screening assay for silencing established HIV-1 macrophage infection identifies nucleoside analogs that perturb H3K9me3 on proviral genomes.
    J Virol. 2023 Aug 14:e0065323. doi: 10.1128/jvi.00653.
    PubMed     Abstract available


  67. LLEWELLYN GN, Chen HY, Rogers GL, Huang X, et al
    Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides.
    J Virol. 2023 Aug 9:e0068423. doi: 10.1128/jvi.00684.
    PubMed     Abstract available


    July 2023
  68. JENSEN JL, Sankhala RS, Dussupt V, Bai H, et al
    Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
    J Virol. 2023 Jul 3:e0159622. doi: 10.1128/jvi.01596.
    PubMed     Abstract available


    June 2023
  69. WEAVER N, Hammonds J, Ding L, Lerner G, et al
    KIF16B Mediates Anterograde Transport and Modulates Lysosomal Degradation of the HIV-1 Envelope Glycoprotein.
    J Virol. 2023 Jun 26:e0025523. doi: 10.1128/jvi.00255.
    PubMed     Abstract available


  70. ORTIZ AM, Castello Casta F, Rahmberg A, Markowitz TE, et al
    2-Hydroxypropyl-beta-Cyclodextrin Treatment Induces Modest Immune Activation in Healthy Rhesus Macaques.
    J Virol. 2023 Jun 20:e0060023. doi: 10.1128/jvi.00600.
    PubMed     Abstract available


  71. VAIDYANATHAN A, Taylor HE, Hope TJ, D'Aquila RT, et al
    Analysis of the Contribution of 6-mer Seed Toxicity to HIV-1-Induced Cytopathicity.
    J Virol. 2023 Jun 13:e0065223. doi: 10.1128/jvi.00652.
    PubMed     Abstract available


  72. PETERSEN M, Lotke R, Hopfensperger K, Victoria S, et al
    Inhibition of Infectious HIV-1 Production by Rerouting the Cellular Furin Inhibitor Serpin B8.
    J Virol. 2023 Jun 5:e0029423. doi: 10.1128/jvi.00294.
    PubMed     Abstract available


    May 2023
  73. YUAN Z, Huang Y, Sadikot RT
    Long Noncoding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promotes HIV-1 Replication through Modulating microRNAs in Macrophages.
    J Virol. 2023 May 31:e0005323. doi: 10.1128/jvi.00053.
    PubMed     Abstract available


  74. ZHOU R, Zhang S, Nguyen HT, Ding H, et al
    Conformations of Human Immunodeficiency Virus Envelope Glycoproteins in Detergents and Styrene-Maleic Acid Lipid Particles.
    J Virol. 2023 May 31:e0032723. doi: 10.1128/jvi.00327.
    PubMed     Abstract available


  75. ZHANG RZ, Mele V, Robben L, Kane M, et al
    Genetic Differences between 129S Substrains Affect Antiretroviral Immune Responses.
    J Virol. 2023;97:e0193022.
    PubMed     Abstract available


  76. SAMER S, Chowdhury A, Wiche Salinas TR, Estrada PMDR, et al
    Lymph-Node-Based CD3(+) CD20(+) Cells Emerge from Membrane Exchange between T Follicular Helper Cells and B Cells and Increase Their Frequency following Simian Immunodeficiency Virus Infection.
    J Virol. 2023 May 23:e0176022. doi: 10.1128/jvi.01760.
    PubMed     Abstract available


  77. MALIKOV V, Naghavi MH
    FEZ1 Plays Dual Roles in Early HIV-1 Infection by Independently Regulating Capsid Transport and Host Interferon-Stimulated Gene Expression.
    J Virol. 2023 May 23:e0049923. doi: 10.1128/jvi.00499.
    PubMed     Abstract available


  78. OLIVEIRA MF, Pankow A, Vollbrecht T, Kumar NM, et al
    Evaluation of Archival HIV DNA in Brain and Lymphoid Tissues.
    J Virol. 2023 May 15:e0054323. doi: 10.1128/jvi.00543.
    PubMed     Abstract available


  79. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
    HIV-1 3'-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles.
    J Virol. 2023 May 1:e0036123. doi: 10.1128/jvi.00361.
    PubMed     Abstract available


    April 2023
  80. SCHATZ M, Marty L, Ounadjela C, Tong PBV, et al
    A Tripartite Complex HIV-1 Tat-Cyclophilin A-Capsid Protein Enables Tat Encapsidation That Is Required for HIV-1 Infectivity.
    J Virol. 2023;97:e0027823.
    PubMed     Abstract available


  81. SASTRY M, Changela A, Gorman J, Xu K, et al
    Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.
    J Virol. 2023 Apr 26:e0160422. doi: 10.1128/jvi.01604.
    PubMed     Abstract available


  82. YIM LY, Lam KS, Luk TY, Mo Y, et al
    Transforming Growth Factor beta Signaling Promotes HIV-1 Infection in Activated and Resting Memory CD4(+) T Cells.
    J Virol. 2023 Apr 12:e0027023. doi: 10.1128/jvi.00270.
    PubMed     Abstract available


    March 2023
  83. CHAPPELL DL, Sandhu PK, Wong JP, Bhatt AP, et al
    KSHV Viral Protein Kinase Interacts with USP9X to Modulate the Viral Lifecycle.
    J Virol. 2023;97:e0176322.
    PubMed     Abstract available


  84. STAMOS JD, Rahman MA, Gorini G, Silva de Castro I, et al
    Effect of Passive Administration of Monoclonal Antibodies Recognizing Simian Immunodeficiency Virus (SIV) V2 in CH59-Like Coil/Helical or beta-Sheet Conformations on Time of SIV(mac251) Acquisition.
    J Virol. 2023 Mar 28:e0186422. doi: 10.1128/jvi.01864.
    PubMed     Abstract available


  85. MALLARINO-HAEGER C, Pino M, Viox EG, Pagliuzza A, et al
    HIV-1 DNA and Immune Activation Levels Differ for Long-Lived T-Cells in Lymph Nodes, Compared with Peripheral Blood, during Antiretroviral Therapy.
    J Virol. 2023 Mar 27:e0167022. doi: 10.1128/jvi.01670.
    PubMed     Abstract available


  86. LU Y, Pang W, Zhang MD, Song JH, et al
    A Novel Vpu Adaptive Mutation of HIV-1 Degrades Tetherin in Northern Pig-Tailed Macaques (Macaca leonina) Mainly via the Ubiquitin-Proteasome Pathway and Increases Viral Release.
    J Virol. 2023 Mar 27:e0020023. doi: 10.1128/jvi.00200.
    PubMed     Abstract available


  87. DESROSIERS RC
    The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.
    J Virol. 2023 Mar 14:e0021123. doi: 10.1128/jvi.00211.
    PubMed     Abstract available


    February 2023
  88. NGUYEN HT, Wang Q, Anang S, Sodroski JG, et al
    Characterization of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformational States on Infectious Virus Particles.
    J Virol. 2023 Feb 23:e0185722. doi: 10.1128/jvi.01857.
    PubMed     Abstract available


  89. OHKURA S, Horie M, Shimizu M, Nakagawa S, et al
    Characterization of Megabat-Favored, CA-Dependent Susceptibility to Retrovirus Infection.
    J Virol. 2023 Feb 13:e0180322. doi: 10.1128/jvi.01803.
    PubMed     Abstract available


  90. KURIAKOSE GIFT S, Wieczorek L, Sanders-Buell E, Zemil M, et al
    Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.
    J Virol. 2023 Feb 7:e0163522. doi: 10.1128/jvi.01635.
    PubMed     Abstract available


  91. WAGNER V, Sabachvili M, Bendl E, Fuchs J, et al
    The Antiviral Activity of Equine Mx1 against Thogoto Virus Is Determined by the Molecular Structure of Its Viral Specificity Region.
    J Virol. 2023 Feb 7:e0193822. doi: 10.1128/jvi.01938.
    PubMed     Abstract available


    January 2023
  92. DURAN-CASTELLS C, Llano A, Kawana-Tachikawa A, Prats A, et al
    Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.
    J Virol. 2023 Jan 31:e0165522. doi: 10.1128/jvi.01655.
    PubMed     Abstract available


  93. MUKIM A, Smith DM, Deshmukh S, Qazi AA, et al
    A Camptothetin Analog, Topotecan, Promotes HIV Latency via Interference with HIV Transcription and RNA Splicing.
    J Virol. 2023 Jan 31:e0163022. doi: 10.1128/jvi.01630.
    PubMed     Abstract available


  94. WRAPP D, Mu Z, Thakur B, Janowska K, et al
    Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield.
    J Virol. 2023 Jan 12:e0167322. doi: 10.1128/jvi.01673.
    PubMed     Abstract available


  95. LISTA MJ, Ficarelli M, Wilson H, Kmiec D, et al
    A Nuclear Export Signal in KHNYN Required for Its Antiviral Activity Evolved as ZAP Emerged in Tetrapods.
    J Virol. 2023 Jan 12:e0087222. doi: 10.1128/jvi.00872.
    PubMed     Abstract available


  96. TEMEROZO JR, Ferreira PLC, Linhares-Lacerda L, Vieira RC, et al
    Interleukin-27 Promotes Divergent Effects on HIV-1 Infection in Peripheral Blood Mononuclear Cells through BST-2/Tetherin.
    J Virol. 2023 Jan 5:e0175222. doi: 10.1128/jvi.01752.
    PubMed     Abstract available


    December 2022
  97. KIM S, Filsinger Interrante MV, Kim PS
    Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies.
    J Virol. 2022 Dec 21:e0164722. doi: 10.1128/jvi.01647.
    PubMed     Abstract available


  98. WEDRYCHOWSKI A, Martin HA, Li Y, Telwatte S, et al
    Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control.
    J Virol. 2022 Dec 21:e0125422. doi: 10.1128/jvi.01254.
    PubMed     Abstract available


  99. PAL S, Jaiswal V, Nala N, Ranga U, et al
    Enhanced Transcriptional Strength of HIV-1 Subtype C Minimizes Gene Expression Noise and Confers Stability to the Viral Latent State.
    J Virol. 2022 Dec 19:e0137622. doi: 10.1128/jvi.01376.
    PubMed     Abstract available


  100. NAZLI A, Chow R, Zahoor MA, Workenhe ST, et al
    LAMP3/CD63 Expression in Early and Late Endosomes in Human Vaginal Epithelial Cells Is Associated with Enhancement of HSV-2 Infection.
    J Virol. 2022;96:e0155322.
    PubMed     Abstract available


  101. WOOLLEY G, Mosher M, Kroll K, Jones R, et al
    Natural Killer Cells Regulate Acute SIV Replication, Dissemination, and Inflammation, but Do Not Impact Independent Transmission Events.
    J Virol. 2022 Dec 13:e0151922. doi: 10.1128/jvi.01519.
    PubMed     Abstract available


  102. MATSUMOTO K, Kuwata T, Tolbert WD, Richard J, et al
    Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates.
    J Virol. 2022 Dec 13:e0163822. doi: 10.1128/jvi.01638.
    PubMed     Abstract available


  103. CHEN Y, Wu Y, Chen S, Zhan Q, et al
    Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
    J Virol. 2022 Dec 5:e0124522. doi: 10.1128/jvi.01245.
    PubMed     Abstract available


  104. MANDIZVO T, Gumede N, Ndlovu B, Ndlovu S, et al
    Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
    J Virol. 2022 Dec 1:e0127022. doi: 10.1128/jvi.01270.
    PubMed     Abstract available


    November 2022
  105. MARTIN HA, Kadiyala GN, Telwatte S, Wedrychowski A, et al
    New Assay Reveals Vast Excess of Defective over Intact HIV-1 Transcripts in Antiretroviral Therapy-Suppressed Individuals.
    J Virol. 2022 Nov 30:e0160522. doi: 10.1128/jvi.01605.
    PubMed     Abstract available


  106. YANG Z, Dam KA, Gershoni JM, Zolla-Pazner S, et al
    Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers.
    J Virol. 2022 Nov 30:e0108222. doi: 10.1128/jvi.01082.
    PubMed     Abstract available


  107. CHANDRASEKAR AP, Cummins NW, Natesampillai S, Misra A, et al
    The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model.
    J Virol. 2022 Nov 30:e0173022. doi: 10.1128/jvi.01730.
    PubMed     Abstract available


  108. DUNHAM D, Viswanathan P, Gill J, Manzano M, et al
    Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
    J Virol. 2022 Nov 23:e0136022. doi: 10.1128/jvi.01360.
    PubMed     Abstract available


  109. HARWOOD OE, Balgeman AJ, Weaver AJ, Ellis-Connell AL, et al
    Transient T Cell Expansion, Activation, and Proliferation in Therapeutically Vaccinated Simian Immunodeficiency Virus-Positive Macaques Treated with N-803.
    J Virol. 2022 Nov 15:e0142422. doi: 10.1128/jvi.01424.
    PubMed     Abstract available


  110. SHARIFI HJ, Paine DN, Fazzari VA, Tipple AF, et al
    Sulforaphane Reduces SAMHD1 Phosphorylation To Protect Macrophages from HIV-1 Infection.
    J Virol. 2022 Nov 15:e0118722. doi: 10.1128/jvi.01187.
    PubMed     Abstract available


  111. FERNANDEZ-DE CESPEDES MV, Hoffman HK, Carter H, Simons LM, et al
    Rab11-FIP1C Is Dispensable for HIV-1 Replication in Primary CD4(+) T Cells, but Its Role Is Cell Type Dependent in Immortalized Human T-Cell Lines.
    J Virol. 2022 Nov 10:e0087622. doi: 10.1128/jvi.00876.
    PubMed     Abstract available


  112. RODRIGUEZ W, Mehrmann T, Hatfield D, Muller M, et al
    Shiftless Restricts Viral Gene Expression and Influences RNA Granule Formation during Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication.
    J Virol. 2022 Nov 3:e0146922. doi: 10.1128/jvi.01469.
    PubMed     Abstract available


  113. ZHANG Y, Chikata T, Kuse N, Murakoshi H, et al
    Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele.
    J Virol. 2022 Nov 3:e0124822. doi: 10.1128/jvi.01248.
    PubMed     Abstract available


    October 2022
  114. GRUENBACH M, Muller CKS, Schlaepfer E, Baroncini L, et al
    cART Restores Transient Responsiveness to IFN Type 1 in HIV-Infected Humanized Mice.
    J Virol. 2022 Oct 17:e0082722. doi: 10.1128/jvi.00827.
    PubMed     Abstract available


  115. WANG Y, Zhao K, Zhao Y, Zhao Z, et al
    Nef Suppresses LINE-1 Retrotransposition through Two Distinct Mechanisms.
    J Virol. 2022 Oct 5:e0114822. doi: 10.1128/jvi.01148.
    PubMed     Abstract available


  116. DUAN Y, Wang X, Sun K, Lin Y, et al
    SYNJ2BP Improves the Production of Lentiviral Envelope Protein by Facilitating the Formation of Mitochondrion-Associated Endoplasmic Reticulum Membrane.
    J Virol. 2022 Oct 5:e0054922. doi: 10.1128/jvi.00549.
    PubMed     Abstract available


  117. ELLIS-CONNELL AL, Balgeman AJ, Harwood OE, Moriarty RV, et al
    Control of Simian Immunodeficiency Virus Infection in Prophylactically Vaccinated, Antiretroviral Treatment-Naive Macaques Is Required for the Most Efficacious CD8 T Cell Response during Treatment with the Interleukin-15 Superagonist N-803.
    J Virol. 2022 Oct 3:e0118522. doi: 10.1128/jvi.01185.
    PubMed     Abstract available


    September 2022
  118. NGUYEN HT, Kuse N, Zhang Y, Murakoshi H, et al
    Control of HIV-1 Replication by CD8(+) T Cells Specific for Two Novel Pol Protective Epitopes in HIV-1 Subtype A/E Infection.
    J Virol. 2022 Sep 26:e0081122. doi: 10.1128/jvi.00811.
    PubMed     Abstract available


  119. SAPP N, Burge N, Cox K, Prakash P, et al
    HIV-1 Preintegration Complex Preferentially Integrates the Viral DNA into Nucleosomes Containing Trimethylated Histone 3-Lysine 36 Modification and Flanking Linker DNA.
    J Virol. 2022 Sep 12:e0101122. doi: 10.1128/jvi.01011.
    PubMed     Abstract available


  120. ZHANG X, Li J, Zhang M, Bai B, et al
    A Novel, Fully Spliced, Accessory Gene in Equine Lentivirus with Distinct Rev-Responsive Element.
    J Virol. 2022 Sep 7:e0098622. doi: 10.1128/jvi.00986.
    PubMed     Abstract available


    August 2022
  121. FILES JK, Sterrett S, Henostroza S, Fucile C, et al
    HLA-II-Associated HIV-1 Adaptation Decreases CD4(+) T-Cell Responses in HIV-1 Vaccine Recipients.
    J Virol. 2022 Aug 24:e0119122. doi: 10.1128/jvi.01191.
    PubMed     Abstract available


  122. HE X, Aid M, Ventura JD, Borducchi E, et al
    Rapid Loss of CD4 T Cells by Pyroptosis during Acute SIV Infection in Rhesus Macaques.
    J Virol. 2022 Aug 24:e0080822. doi: 10.1128/jvi.00808.
    PubMed     Abstract available


  123. ANANG S, Richard J, Bourassa C, Goyette G, et al
    Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
    J Virol. 2022 Aug 18:e0063622. doi: 10.1128/jvi.00636.
    PubMed     Abstract available


  124. WOODBURN BM, Kanchi K, Zhou S, Colaianni N, et al
    Characterization of Macrophage-Tropic HIV-1 Infection of Central Nervous System Cells and the Influence of Inflammation.
    J Virol. 2022 Aug 17:e0095722. doi: 10.1128/jvi.00957.
    PubMed     Abstract available


  125. DUAN S, Yu X, Wang C, Meng L, et al
    Dominant Negative Mutants of Human Immunodeficiency Virus Type 1 Viral Infectivity Factor (Vif) Disrupt Core-Binding Factor Beta-Vif Interaction.
    J Virol. 2022 Aug 11:e0055522. doi: 10.1128/jvi.00555.
    PubMed     Abstract available


  126. JONES ST, Guo K, Cooper EH, Dillon SM, et al
    Altered Immunoglobulin Repertoire and Decreased IgA Somatic Hypermutation in the Gut during Chronic HIV-1 Infection.
    J Virol. 2022 Aug 8:e0097622. doi: 10.1128/jvi.00976.
    PubMed     Abstract available


  127. WANG XQ, Zerbato JM, Avihingsanon A, Fisher K, et al
    Markers of Immune Activation and Inflammation Are Associated with Higher Levels of Genetically-Intact HIV in HIV-HBV Co-Infected Individuals.
    J Virol. 2022 Aug 2:e0058822. doi: 10.1128/jvi.00588.
    PubMed     Abstract available


  128. BUCKMASTER MV, Goff SP
    Riplet Binds the Zinc Finger Antiviral Protein (ZAP) and Augments ZAP-Mediated Restriction of HIV-1.
    J Virol. 2022 Aug 1:e0052622. doi: 10.1128/jvi.00526.
    PubMed     Abstract available


    July 2022
  129. RUDICELL RS, Piel AK, Stewart F, Moore DL, et al
    Correction for Rudicell et al., "High Prevalence of Simian Immunodeficiency Virus Infection in a Community of Savanna Chimpanzees".
    J Virol. 2022 Jul 26:e0045122. doi: 10.1128/jvi.00451.
    PubMed    


  130. WIETGREFE SW, Duan L, Anderson J, Marques G, et al
    Detecting Sources of Immune Activation and Viral Rebound in HIV Infection.
    J Virol. 2022 Jul 20:e0088522. doi: 10.1128/jvi.00885.
    PubMed     Abstract available


  131. ALBALAWI YA, Narasipura SD, Olivares LJ, Al-Harthi L, et al
    CD4(dim) CD8(bright) T Cells Home to the Brain and Mediate HIV Neuroinvasion.
    J Virol. 2022 Jul 19:e0080422. doi: 10.1128/jvi.00804.
    PubMed     Abstract available


  132. MACEDO AB, Levinger C, Nguyen BN, Richard J, et al
    The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation.
    J Virol. 2022 Jul 14:e0037222. doi: 10.1128/jvi.00372.
    PubMed     Abstract available


  133. BAKER EJ, Hughes K, Travieso T, Klotman ME, et al
    Establishment, Persistence, and Reactivation of Latent HIV-1 Infection in Renal Epithelial Cells.
    J Virol. 2022 Jul 5:e0062422. doi: 10.1128/jvi.00624.
    PubMed     Abstract available


  134. RATCLIFF AN, Venner CM, Olabode AS, Knapp J, et al
    Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.
    J Virol. 2022 Jul 5:e0185121. doi: 10.1128/jvi.01851.
    PubMed     Abstract available


    June 2022
  135. HOFFMAN HK, Aguilar RS, Clark AR, Groves NS, et al
    Endocytosed HIV-1 Envelope Glycoprotein Traffics to Rab14(+) Late Endosomes and Lysosomes to Regulate Surface Levels in T-Cell Lines.
    J Virol. 2022 Jun 30:e0076722. doi: 10.1128/jvi.00767.
    PubMed     Abstract available


  136. KAO S, Miyagi E, Mallorson R, Saito H, et al
    The Myeloid-Specific Transcription Factor PU.1 Upregulates Mannose Receptor Expression but Represses Basal Activity of the HIV-LTR Promoter.
    J Virol. 2022 Jun 29:e0065222. doi: 10.1128/jvi.00652.
    PubMed     Abstract available


  137. AVILA-RIOS S, Garcia-Morales C, Reyes-Teran G, Gonzalez-Rodriguez A, et al
    Phylodynamics of HIV in the Mexico City Metropolitan Region.
    J Virol. 2022 Jun 28:e0070822. doi: 10.1128/jvi.00708.
    PubMed     Abstract available


  138. RICHETTA C, Subra F, Malet I, Leh H, et al
    Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.
    J Virol. 2022 Jun 27:e0067622. doi: 10.1128/jvi.00676.
    PubMed     Abstract available


  139. SHEWARD DJ, Hermanus T, Murrell B, Garrett N, et al
    HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies.
    J Virol. 2022 Jun 27:e0032422. doi: 10.1128/jvi.00324.
    PubMed     Abstract available


  140. PEDERSEN SF, Collora JA, Kim RN, Yang K, et al
    Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen.
    J Virol. 2022 Jun 22:e0057722. doi: 10.1128/jvi.00577.
    PubMed     Abstract available


  141. LIN J, Law R, Korosec CS, Zhou C, et al
    Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity.
    J Virol. 2022 Jun 14:e0050922. doi: 10.1128/jvi.00509.
    PubMed     Abstract available


  142. JOSEPH KW, Halvas EK, Brandt LD, Patro SC, et al
    Deep Sequencing Analysis of Individual HIV-1 Proviruses Reveals Frequent Asymmetric Long Terminal Repeats.
    J Virol. 2022 Jun 8:e0012222. doi: 10.1128/jvi.00122.
    PubMed     Abstract available


  143. ROJAS CHAVEZ RA, Boyt D, Schwery N, Han C, et al
    Commonly Elicited Antibodies against the Base of the HIV-1 Env Trimer Guide the Population-Level Evolution of a Structure-Regulating Region in gp41.
    J Virol. 2022 Jun 6:e0040622. doi: 10.1128/jvi.00406.
    PubMed     Abstract available


    May 2022
  144. KLEINMAN AJ, Sivanandham S, Sette P, Sivanandham R, et al
    Changes to the Simian Immunodeficiency Virus (SIV) Reservoir and Enhanced SIV-Specific Responses in a Rhesus Macaque Model of Functional Cure after Serial Rounds of Romidepsin Administrations.
    J Virol. 2022 May 31:e0044522. doi: 10.1128/jvi.00445.
    PubMed     Abstract available


  145. PETERS RJ, Stevenson M
    Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-kappaB Activity.
    J Virol. 2022 May 23:e0048422. doi: 10.1128/jvi.00484.
    PubMed     Abstract available


  146. PEI Z, Wang H, Zhao Z, Chen X, et al
    Chemokine PF4 Inhibits EV71 and CA16 Infections at the Entry Stage.
    J Virol. 2022 May 17:e0043522. doi: 10.1128/jvi.00435.
    PubMed     Abstract available


  147. TU JJ, Kumar A, Giorgi EE, Eudailey J, et al
    Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    J Virol. 2022 May 10:e0023122. doi: 10.1128/jvi.00231.
    PubMed     Abstract available


  148. SACKS D, Wiehe K, Morris L, Moore PL, et al
    Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
    J Virol. 2022 May 5:e0027022. doi: 10.1128/jvi.00270.
    PubMed     Abstract available


  149. BUTTA GM, Bozzi G, Gallo G, Copaloni G, et al
    Heterogeneity of Latency Establishment in the Different Human CD4(+) T Cell Subsets Stimulated with IL-15.
    J Virol. 2022 May 2:e0037922. doi: 10.1128/jvi.00379.
    PubMed     Abstract available


    April 2022
  150. CIENIEWICZ B, Kirillov V, Daher I, Li X, et al
    IKKalpha-Mediated Noncanonical NF-kappaB Signaling Is Required To Support Murine Gammaherpesvirus 68 Latency In Vivo.
    J Virol. 2022 Apr 28:e0002722. doi: 10.1128/jvi.00027.
    PubMed     Abstract available


  151. CHIKATA T, Paes W, Kuse N, Partridge T, et al
    Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection.
    J Virol. 2022 Apr 27:e0043222. doi: 10.1128/jvi.00432.
    PubMed     Abstract available


  152. TABLER CO, Wegman SJ, Chen J, Shroff H, et al
    The HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release.
    J Virol. 2022 Apr 19:e0219821. doi: 10.1128/jvi.02198.
    PubMed     Abstract available


  153. RESOP RS, Bosque A
    Pharmacological Targeting of Sphingosine Kinases Impedes HIV-1 Infection of CD4 T Cells through SAMHD1 Modulation.
    J Virol. 2022 Apr 12:e0009622. doi: 10.1128/jvi.00096.
    PubMed     Abstract available


  154. KLASSE PJ, Moore JP
    Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.
    J Virol. 2022 Apr 6:e0003422. doi: 10.1128/jvi.00034.
    PubMed     Abstract available


    March 2022
  155. NGUYEN HT, Qualizza A, Anang S, Zhao M, et al
    Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation.
    J Virol. 2022 Mar 28:e0166821. doi: 10.1128/jvi.01668.
    PubMed     Abstract available


  156. LU F, Zankharia U, Vladimirova O, Yi Y, et al
    Epigenetic Landscape of HIV-1 Infection in Primary Human Macrophage.
    J Virol. 2022 Mar 23:e0016222. doi: 10.1128/jvi.00162.
    PubMed     Abstract available


  157. HOTZEL I
    Deep-Time Structural Evolution of Retroviral and Filoviral Surface Envelope Proteins.
    J Virol. 2022 Mar 23:e0006322. doi: 10.1128/jvi.00063.
    PubMed     Abstract available


  158. XIANG J, Lu M, Shi M, Cheng X, et al
    Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
    J Virol. 2022 Mar 23:e0005722. doi: 10.1128/jvi.00057.
    PubMed     Abstract available


  159. YERO A, Farnos O, Clain J, Zghidi-Abouzid O, et al
    Impact of Early ARV Initiation on Relative Proportions of Effector and Regulatory CD8 T Cell in Mesenteric Lymph Nodes and Peripheral Blood During Acute SIV Infection of Rhesus Macaques.
    J Virol. 2022 Mar 21:e0025522. doi: 10.1128/jvi.00255.
    PubMed     Abstract available


  160. COGSWELL A, Jo S, Ferguson N, Gupta K, et al
    Presence of Natural Killer B Cells in Simian Immunodeficiency Virus-Infected Colon That Have Properties and Functions Similar to Those of Natural Killer Cells and B Cells but Are a Distinct Cell Population.
    J Virol. 2022 Mar 21:e0023522. doi: 10.1128/jvi.00235.
    PubMed     Abstract available


  161. ANWAR A, Helou M, Hervol J, Levine AD, et al
    Impact of Caveolin-Mediated Endocytosis on the Trafficking of HIV within the Colonic Barrier.
    J Virol. 2022 Mar 17:e0020222. doi: 10.1128/jvi.00202.
    PubMed     Abstract available


  162. CHEN SMY, Wong YC, Yim LY, Zhang H, et al
    Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine.
    J Virol. 2022 Mar 17:e0216121. doi: 10.1128/jvi.02161.
    PubMed     Abstract available


  163. BRICKER KM, Obregon-Perko V, Williams B, Oliver D, et al
    Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants.
    J Virol. 2022 Mar 16:e0169921. doi: 10.1128/jvi.01699.
    PubMed     Abstract available


  164. WANG Q, Esnault F, Zhao M, Chiu TJ, et al
    Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes.
    J Virol. 2022 Mar 15:e0187821. doi: 10.1128/jvi.01878.
    PubMed     Abstract available


  165. CARLIN E, Greer B, Lowman K, Dalecki AG, et al
    Lentiviral Nef Proteins Differentially Govern the Establishment of Viral Latency.
    J Virol. 2022 Mar 10:e0220621. doi: 10.1128/jvi.02206.
    PubMed     Abstract available


    February 2022
  166. FISHER K, Wang XQ, Lee A, Morcilla V, et al
    Plasma-Derived HIV-1 Virions Contain Considerable Levels of Defective Genomes.
    J Virol. 2022 Feb 24:jvi0201121. doi: 10.1128/jvi.02011.
    PubMed     Abstract available


  167. ELSAYED H, Nabi G, McKinstry WJ, Khoo KK, et al
    Correction for Elsayed et al., "Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines".
    J Virol. 2022;96:e0195421.
    PubMed    


  168. MIKI S, Kawai Y, Nakayama-Hosoya K, Iwabuchi R, et al
    Sustainable antiviral efficacy of rejuvenated HIV-specific cytotoxic T lymphocytes generated from induced pluripotent stem cells.
    J Virol. 2022 Feb 2:jvi0221721. doi: 10.1128/jvi.02217.
    PubMed     Abstract available


    January 2022
  169. PREVOST J, Richard J, Gasser R, Medjahed H, et al
    Detection of the HIV-1 accessory proteins Nef and Vpu by flow cytometry represents a new tool to study their functional interplay within a single infected CD4+ T cell.
    J Virol. 2022 Jan 26:jvi0192921. doi: 10.1128/jvi.01929.
    PubMed     Abstract available


  170. OHATA Y, Tomonaga M, Watanabe Y, Tomura K, et al
    Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor, JTP-0157602.
    J Virol. 2022 Jan 19:JVI0184321. doi: 10.1128/JVI.01843.
    PubMed     Abstract available


  171. RICHTER E, Bornemann L, Korencak M, Alter G, et al
    Reduction of CD8 T cell functionality but not inhibitory capacity by integrase inhibitors.
    J Virol. 2022 Jan 12:JVI0173021. doi: 10.1128/JVI.01730.
    PubMed     Abstract available


  172. DALECKI AG, Greer BD, Duverger A, Strange EL, et al
    Host T cell dedifferentiation effects drive HIV-1 latency stability.
    J Virol. 2022 Jan 12:jvi0197421. doi: 10.1128/jvi.01974.
    PubMed     Abstract available


    December 2021
  173. VAN DORSTEN RT, Reh L, Trkola A, Morris L, et al
    Single-chain variable fragments of broadly neutralizing antibodies prevent HIV cell-cell transmission.
    J Virol. 2021 Dec 22:jvi0193421. doi: 10.1128/jvi.01934.
    PubMed     Abstract available


  174. ETTICH J, Werner J, Weitz HT, Mueller E, et al
    A hybrid soluble gp130/spike-nanobody fusion protein simultaneously blocks IL-6 trans-signaling and cellular infection with SARS-CoV2.
    J Virol. 2021 Dec 22:JVI0162221. doi: 10.1128/JVI.01622.
    PubMed     Abstract available


  175. CHESARINO NM, Emerman M
    HIV-1 Vif gained breadth in APOBEC3G specificity after cross-species transmission of its precursors.
    J Virol. 2021 Dec 15:JVI0207121. doi: 10.1128/JVI.02071.
    PubMed     Abstract available


  176. HANY L, Turmel MO, Barat C, Ouellet M, et al
    Bryostatin-1 decreases HIV-1 infection and viral production in human primary macrophages.
    J Virol. 2021 Dec 8:JVI0195321. doi: 10.1128/JVI.01953.
    PubMed     Abstract available


  177. YAO W, Strebel K, Yamaoka S, Yoshida T, et al
    SIVgsn-99CM71 Vpu employs different amino acids to antagonize human and greater spot-nosed monkey BST-2.
    J Virol. 2021 Dec 8:JVI0152721. doi: 10.1128/JVI.01527.
    PubMed     Abstract available


    November 2021
  178. HOLGUIN L, Echavarria L, Burnetta JC
    Novel humanized-PBMC mouse model with delayed onset of GVHD for preclinical HIV research.
    J Virol. 2021 Nov 24:JVI0139421. doi: 10.1128/JVI.01394.
    PubMed     Abstract available


  179. WU C, He Y, Zhao J, Luo K, et al
    Exacerbated AIDS progression by PD-1 blockade during therapeutic vaccination in chronically SIV-infected rhesus macaques after ART treatment interruption.
    J Virol. 2021 Nov 24:JVI0178521. doi: 10.1128/JVI.01785.
    PubMed     Abstract available


  180. BELLON M, Nicot C
    Feedback Loop Regulation Between Pim Kinases and Tax Keeps HTLV-I Viral Replication in Check.
    J Virol. 2021 Nov 24:JVI0196021. doi: 10.1128/JVI.01960.
    PubMed     Abstract available


  181. ALVARADO-HERNANDEZ B, Ma Y, Sharma NR, Majerciak V, et al
    Protein-RNA interactome analysis reveals wide association of KSHV ORF57 with host non-coding RNAs and polysomes.
    J Virol. 2021 Nov 17:JVI0178221. doi: 10.1128/JVI.01782.
    PubMed     Abstract available


  182. HEMSATH JR, Liaci AM, Rubin JD, Parrett BJ, et al
    Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26).
    J Virol. 2021 Nov 17:JVI0082621. doi: 10.1128/JVI.00826.
    PubMed     Abstract available


  183. VIEIRA VA, Adland E, Grayson NE, Csala A, et al
    Two distinct mechanisms leading to loss of virological control in the rare group of antiretroviral therapy-naive, transiently aviraemic children living with HIV.
    J Virol. 2021 Nov 10:JVI0153521. doi: 10.1128/JVI.01535.
    PubMed     Abstract available


  184. CHEN J, Zhao S, Cui Z, Li W, et al
    MicroRNA-376b-3p Promotes Porcine Reproductive and Respiratory Syndrome Virus Replication by Targeting Viral Restriction Factor TRIM22.
    J Virol. 2021 Nov 10:JVI0159721. doi: 10.1128/JVI.01597.
    PubMed     Abstract available


  185. WANG XF, Wang YH, Bai B, Zhang M, et al
    Truncation of the Cytoplasmic Tail of Equine Infectious Anemia Virus Increases Virion Production by Improving Env Cleavage and Plasma Membrane Localization.
    J Virol. 2021;95:e0108721.
    PubMed     Abstract available


  186. DUGGAN NN, Weisgrau KL, Magnani DM, Rakasz EG, et al
    SOSIP trimer-specific antibodies isolated from a SHIV-infected monkey with versus without a pre-blocking step with gp41.
    J Virol. 2021 Nov 3:JVI0158221. doi: 10.1128/JVI.01582.
    PubMed     Abstract available


  187. MIELKE D, Stanfield-Oakley S, Borate B, Fisher LH, et al
    Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies.
    J Virol. 2021 Nov 3:JVI0164321. doi: 10.1128/JVI.01643.
    PubMed     Abstract available


  188. GACH JS, Matsuno SY, Mercado M, Hangartner L, et al
    Internalization of HIV-1 by phagocytes is increased when virions are opsonized with multimeric antibody in the presence of complement.
    J Virol. 2021 Nov 3:JVI0168921. doi: 10.1128/JVI.01689.
    PubMed     Abstract available


  189. ZHAO Y, Du J, Wang Y, Wang Q, et al
    BST2 suppresses LINE-1 retrotransposition by reducing the promoter activity of LINE-1 5'-UTR.
    J Virol. 2021 Nov 3:JVI0161021. doi: 10.1128/JVI.01610.
    PubMed     Abstract available


    October 2021
  190. YU J, Collins ND, Mercado NB, McMahan K, et al
    Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques.
    J Virol. 2021 Oct 27:JVI0159921. doi: 10.1128/JVI.01599.
    PubMed     Abstract available


  191. HOTZEL I
    Domain Organization of Lentiviral and Betaretroviral Surface Envelope Glycoproteins Modeled with AlphaFold.
    J Virol. 2021 Oct 27:JVI0134821. doi: 10.1128/JVI.01348.
    PubMed     Abstract available


  192. SCHORCHT A, Cottrell CA, Pugach P, Ringe RP, et al
    The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization.
    J Virol. 2021 Oct 20:JVI0155221. doi: 10.1128/JVI.01552.
    PubMed     Abstract available


  193. COLOMER-LLUCH M, Kilpelainen A, Pernas M, Pena R, et al
    Viral and Cellular factors leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors.
    J Virol. 2021 Oct 20:JVI0149921. doi: 10.1128/JVI.01499.
    PubMed     Abstract available


  194. BELTRAN-PAVEZ C, Bontjer I, Gonzalez N, Pernas M, et al
    Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle (VLP) Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    J Virol. 2021 Oct 20:JVI0134321. doi: 10.1128/JVI.01343.
    PubMed     Abstract available


  195. CACCURI F, Neves V, Gano L, Correia JDG, et al
    The HIV-1 matrix protein p17 does cross the Blood-Brain Barrier.
    J Virol. 2021 Oct 20:JVI0120021. doi: 10.1128/JVI.01200.
    PubMed     Abstract available


  196. BENNER BE, Bruce JW, Kentala JR, Murray M, et al
    Perturbing HIV-1 ribosomal frameshifting frequency reveals a cis preference for Gag-Pol incorporation into assembling virions.
    J Virol. 2021 Oct 13:JVI0134921. doi: 10.1128/JVI.01349.
    PubMed     Abstract available


  197. BALAMURUGAN A, Ng HL, Yang OO
    Correction for Balamurugan et al., "Cross-Reactivity against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte Clones".
    J Virol. 2021;95:e0139721.
    PubMed    


  198. SOWD GA, Shi J, Aiken C
    HIV-1 CA inhibitors are antagonized by inositol phosphate stabilization of the viral capsid in cells.
    J Virol. 2021 Oct 6:JVI0144521. doi: 10.1128/JVI.01445.
    PubMed     Abstract available


  199. KURNAEVA MA, Zalevsky AO, Arifulin EA, Lisitsyna OM, et al
    Molecular coevolution of nuclear and nucleolar localization signals inside basic domain of HIV-1 Tat.
    J Virol. 2021 Oct 6:JVI0150521. doi: 10.1128/JVI.01505.
    PubMed     Abstract available


    September 2021
  200. NAGEL L, Kant S, Leeks C, Routy JP, et al
    Evolution of antibodies to native trimeric envelope and their Fc dependent functions in untreated and treated primary HIV infection.
    J Virol. 2021 Sep 29:JVI0162521. doi: 10.1128/JVI.01625.
    PubMed     Abstract available


  201. TORRENTS DE LA PENA A, Del Moral Sanchez I, Burger JA, Bontjer I, et al
    Targeted destabilization of the HIV-1 gp120-gp41 interface leads to convergent evolution with mutations in the V1V2, HR1 and HR2 domains.
    J Virol. 2021 Sep 29:JVI0053221. doi: 10.1128/JVI.00532.
    PubMed     Abstract available


    August 2021
  202. NCHIOUA R, Kmiec D, Gaba A, Sturzel CM, et al
    APOBEC3F Constitutes a Barrier to Successful Cross-Species Transmission of Simian Immunodeficiency Virus SIVsmm to Humans.
    J Virol. 2021;95:e0080821.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.